BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Harbour BioMed Files IND Application in China for Novel Antibody Therapy HBM9378/SKB378 Targeting COPD

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ant...

November 11, 2024 | News

Dizal Submits NDA to U.S. FDA for Sunvozertinib as a New Treatment Option for Advanced NSCLC with EGFR Exon 20 Insertion Mutations

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announ...

November 11, 2024 | News

Aditum Bio and Leads Biolabs Launch Oblenio Bio to Advance First-in-Class Tri-Specific Antibody for Autoimmune Diseases

Aditum Bio and Leads Biolabs announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreeme...

November 08, 2024 | News

Ascletis' ASC47 Shows Promise in Phase I Trial with Once-Monthly Dosing and Superior Fat Reduction in Obesity Treatment

Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed...

November 08, 2024 | News

Minghui Pharmaceutical Announces Promising Phase I Results for MHB039A, a PD-1 x VEGF Bispecific Antibody, in Solid Tumor Treatment in China

Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today annou...

November 07, 2024 | News

China’s Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment

Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody target...

November 07, 2024 | News

Medidata Introduces Oncology and Vaccine Solutions to Streamline Phase II and III Trials with FDA-Aligned Patient-Centric Design

The new products combine Medidata's diverse technologies and experience from thousands of previous trials to streamline the management of Phase II an...

November 05, 2024 | News

Chipscreen Biosciences Secures NMPA Approval for Phase III Trial of Chiauranib in ES-SCLC Treatment

Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Ph...

November 04, 2024 | News

Hong Kong's Akeso Biopharma Advances Immunotherapy in Biliary Tract Cancer with First Patient Enrolled in Phase III Study of Ivonescimab

Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, c...

November 01, 2024 | News

Hong Kong’s Akeso Biopharma Enrolls First Patient in Pioneering Phase III Trial for Advanced Head and Neck Cancer Therapy

Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (A...

October 31, 2024 | News

Clover Biopharmaceuticals' Non-Adjuvanted RSV Vaccine Candidate SCB-1019 Shows Promising Efficacy and Safety in Head-to-Head Comparison with GSK's AREXVY

- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candi...

October 29, 2024 | News